AUTHOR INDEX

Volume 82 • 2000

Aikawa, N. and Ohmori, K.
Antipropulsive effect of zaldaride 350
Amagaya, S. *See* Ikeda, Y.
Aoki, M. *See* Takai, S.
Arai, N. *See* Furukawa, N.
Arakida, Y., Ohga, K., Suwa, K., Okada, Y., Morio, H., Yokota, M., Miyata, K., Yamada, T. and Honda, K.
Effect of YM158 on IAR, LAR and AHR 287
Asai, H. *See* Kinoshita, K.
Aye, N.N. *See* Sugiyama, A.

Baba, K. *See* Guo, L.-Q.
Ban, A. *See* Ito, M.
Banno, K. *See* Tsukimi, Y.
Bartolini, A. *See* Ghelardini, C.
Baum, B.J. *See* Yamano, S.

Cha, S.H., Hahn, T.-W., Sekine, T., Lee, K.-H. and Endou, H.
ATP affects $[Ca^{2+}]_i$ and proliferation in BCEC 181
Chen, Z. *See* Ishizawa, K.
Cheng, Y.N. *See* Wang, Q.L.
Chiba, K. *See* Koriyama, Y.
Chiba, S. *See* Kurogouchi, F.
—— *See* Yang, X.P.

Do, E. *See* Niu, S-.Y.

Ebara, T. *See* Miura, K.
Efange, S.M.N. *See* Sugiyama, A.
Endou, H. *See* Cha, S.H.

Fujihira, E. *See* Ikeda, Y.
Fujii, Y. *See* Ishizawa, K.
Fujita, K. *See* Furukawa, N.
Fujita, R. *See* Miyake, N.
Fukunaga, Y. and Kishioka, S.
Enkephalin and morphine withdrawal 175
Fukushima, T., Nitta, T., Furuichi, H., Izumo, N., Fukuyama, T., Nakamuta, H. and Koida, M.
Bone anabolic effect of PTH(1 – 34) and SCT 240
Fukuyama, T. *See* Fukushima, T.
Furuichi, H. *See* Fukushima, T.
Furukawa, N., Goshima, Y., Miyamae, T., Sugiyama, Y., Shimizu, M., Ohshima, E., Suzuki, F., Arai, N., Fujita, K. and Misu, Y.
Screening of competitive DOPA antagonist 40
Furukawa, Y. *See* Kurogouchi, F.

Galeotti, N. *See* Ghelardini, C.
Gan, Y.H. *See* Niu, S-.Y.
Ghelardini, C., Galeotti, N. and Bartolini, A.
Amitriptyline and imipramine antinociception 130
Goshima, Y. *See* Furukawa, N.
Goshima, Y., Sasaki, Y., Nakayama, T., Ito, Takaaki and Kimura, Toru
Repulsive molecules and neuroregeneration 273
Guo, L.-Q., Taniguchi, M., Xiao, Y.-Q., Baba, K., Ohta, T. and Yamazoe, Y.
Furanocoumarins inhibit CYP3A 122

Haginaka, J. *See* Yamaguchi, Y.
Hahn, T.-W. *See* Cha, S.H.
Haji, A., Okazaki, M. and Takeda, R.
NMDA receptors in E2 neurons 353
Hashimoto, K. *See* Sugiyama, A.
Hashimoto, S. *See* Katoh, Yoko
Hata, F. *See* Nakagawa, M.
—— *See* Nishiwaki, H.
Helmeste, D.M. and Tang, S.W.
Dopamine D_4 receptors 1
Hirase, J. *See* Tsukimi, Y.
Hirose, H., Kimura, Toshifumi, Okada, M., Itoh, Yoshiki, Ishida, F., Mochizuki, N., Nishibe, T. and Nishikibe, M.
NSP-513 and thrombosis 188
Hirose, M. *See* Kurogouchi, F.
Honda, K. *See* Arakida, Y.
Hsu, K.-S. *See* Wu, H.-M.
Huang, C.-C. *See* Wu, H.-M.

Ichihara, T. *See* Tsukimi, Y.
Iino, M.
Ca^{2+} and IP_3 dynamics 15
Iizuka, A. *See* Ikeda, Y.
Ikeda, Y., Iizuka, A., Amagaya, S., Ishige, A., Komatsu, Y. and Fujihira, E.
Anti-allergic activities of MBS 29
Imaizumi, Y. *See* Tokuno, T.
Imanishi, M. *See* Miura, K.
Inoue, S. *See* Nishihara, M.
Irie, Y. *See* Niu, S-.Y.
Ishida, F. *See* Hirose, H.
Ishige, A. *See* Ikeda, Y.
Ishihara, M. *See* Ito, M.
Ishikawa, H. *See* Tsukimi, Y.
Ishikawa, M. *See* Miyake, N.
Ishizawa, K., Chen, Z., Okuma, C., Sugimoto, Y., Fujii, Y. and Kamei, C.
Histamine and GABA in kindled seizures 48
Ito, M., Ban, A. and Ishihara, M.
Anti-ulcer effects of chitin-chitosan 218
Ito, Takaaki *See* Goshima, Y.
Ito, Takashi *See* Yoshimura, M.
Itoh, Yoshiki *See* Hirose, H.
Itoh, Yoshimi *See* Takai, S.
Iwao, H. *See* Miura, K.
Izumo, N. *See* Fukushima, T.

Ji, J.B. *See* Wang, Q.L.
Jin, D. *See* Takai, S.

Kagota, S. *See* Yamaguchi, Y.
Kamei, C. *See* Ishizawa, K.
Kang, T.M. *See* Rhee, J.C.
Kato, Yumi *See* Uchida, M.
Katoh, Yoko, Hashimoto, S., Kimura, J. and Watanabe, T.
Troglitazone and L-type Ca^{2+} channel 102
Kawabata, A. and Kuroda, R.
Protease-activated receptor 171
Kawabata, A. *See* Nishikawa, H.
Kawaguchi, M. *See* Yamagishi, H.

Kawai, K. *See* Nishikawa, H.
Kawai, Y. *See* Yoshimura, M.
Kim, K.W. *See* Rhee, J.C.
Kim, S. *See* Miura, K.
Kimura, J. *See* Katoh, Yoko
Kimura, Toru *See* Goshima, Y.
Kimura, Toshifumi *See* Hirose, H.
Kinoshita, K., Watanabe, Y., Asai, H. and Matsuoka, Y.
3-AP toxicity and partial recovery by TRH 295
Kishioka, S. *See* Fukunaga, Y.
Kobayashi, Y. *See* Kuro, T.
Kohnou, K. *See* Kuro, T.
Koida, M. *See* Fukushima, T.
Koike, K. *See* Satoh, M.
Komatsu, Y. *See* Ikeda, Y.
Kondo, I.
C kinase and capacitative Ca^{2+} entry 210
Koriyama, Y., Yamazaki, M., Chiba, K. and Mohri, T.
Amyloid protein toxicity and prevention 301
Kumar, V. *See* Sugaya, K.
Kunitomo, M. *See* Yamaguchi, Y.
Kuo, C.H. *See* Niu, S-.Y.
Kuro, T., Kohnou, K., Kobayashi, Y., Takaoka, M., Opgenorth, T.J., Wessale, J.L. and Matsumura, Y.
Acute renal failure and endothelin 307
Kuroda, R. *See* Kawabata, A.
—— *See* Nishikawa, H.
Kurogouchi, F., Furukawa, Y., Zhao, D., Hirose, M., Nakajima, K., Tsuboi, M. and Chiba, S.
KB-R7943 on the heart 155

Lee, K.-H. *See* Cha, S.H.
Li, L.-H. *See* Wu, H.-M.
Lurie, K.G. *See* Sugiyama, A.

Maekawa, M., Ono, S., Narita, H., Murayama, T. and Nomura, Y.
Ca^{2+}- and vesicle-independent NA release 59
Manev, H. *See* Sugaya, K.
Matsueda, K. *See* Uchida, M.
Matsumura, E. *See* Takai, S.
Matsumura, Y. *See* Kuro, T.
Matsuoka, Y. *See* Kinoshita, K.
Mayanagi, H. *See* Takahashi, A.
Meng, Y.J. *See* Wang, Q.L.
Miki, N. *See* Niu, S-.Y.
Misu, Y. *See* Furukawa, N.
Mitsui-Saito, M., Nakahata, N. and Ohizumi, Y.
SK&F 96365 depolymerizes microtubules 269
Miura, K., Yamanaka, S., Ebara, T., Okumura, M., Imanishi, M., Kim, S., Nakatani, T. and Iwao, H.
Carboxy-PTIO and endotoxic shock 261
Miyake, N., Fujita, R., Ishikawa, M., Takayanagi, M., Takayanagi, Y. and Sasaki, K.
Reversal of drug resistance by tamolarizine 265
Miyamae, T. *See* Furukawa, N.
Miyata, K. *See* Arakida, Y.
Miyazaki, M. *See* Takai, S.
Mochizuki, N. *See* Hirose, H.
Mohri, T. *See* Koriyama, Y.
Morio, H. *See* Arakida, Y.
Morohashi, T., Ohta, A. and Yamada, S.
Fructooligosaccharides prevent osteopenia 54
Muraki, K. *See* Tokuno, T.
Muraoka, A. *See* Uchida, M.
Muraoka, O. *See* Niu, S-.Y.
Murayama, T. *See* Maekawa, M.

Nagata, K. *See* Nakamura, T.
Nakagawa, M., Takeuchi, T., Niioka, S., Yamaji, M., Okishio, Y., Nishio, H. and Hata, F.
cGMP-PKG-independent effect of ODQ 164
Nakahata, N. *See* Mitsui-Saito, M.
Nakajima, K. *See* Kurogouchi, F.
Nakamura, T., Okada, K., Nagata, K. and Yamazoe, Y.
Intestinal CYP3A induction 232
Nakamuta, H. *See* Fukushima, T.
Nakatani, T. *See* Miura, K.
Nakayama, T. *See* Goshima, Y.
Narita, H. *See* Maekawa, M.
Narita, M. *See* Tsukimi, Y.
Niioka, S. *See* Nakagawa, M.
Nishibe, T. *See* Hirose, H.
Nishida, M. *See* Nishikawa, H.
Nishigaito, T. *See* Tsukimi, Y.
Nishihara, M., Yokotani, K., Inoue, S. and Osumi, Y.
Thromboxane A_2 and hippocampal NA 226
Nishikawa, H., Kawabata, A., Kuroda, R., Nishida, M. and Kawai, K.
Protease-activated receptor in mast cell 74
Nishikibe, M. *See* Hirose, H.
Nishio, H. *See* Nakagawa, M.
—— *See* Nishiwaki, H.
Nishiwaki, H., Saitoh, N., Nishio, H., Takeuchi, T. and Hata, F.
Role of K^+ channels in ACh release 343
Nitta, T. *See* Fukushima, T.
Niu, S-.Y., Kuo, C.H., Taira, E., Muraoka, O., Irie, Y., Gan, Y.H., Do, E. and Miki, N.
Naloxone inhibition of NF-68 promoter 34
Nomura, Y. *See* Maekawa, M.

Ohga, K. *See* Arakida, Y.
Ohizumi, Y. *See* Mitsui-Saito, M.
Ohmori, K. *See* Aikawa, N.
Ohshima, E. *See* Furukawa, N.
Ohta, A. *See* Morohashi, T.
Ohta, T. *See* Guo, L.-Q.
Okada, K. *See* Nakamura, T.
Okada, M. *See* Hirose, H.
Okada, Y. *See* Arakida, Y.
Okazaki, M. *See* Haji, A.
Okishio, Y. *See* Nakagawa, M.
Okuma, C. *See* Ishizawa, K.
Okumura, M. *See* Miura, K.
Ono, S. *See* Maekawa, M.
Onodera, K. *See* Takahashi, A.
Opgenorth, T.J. *See* Kuro, T.
Osumi, Y. *See* Nishihara, M.
Ozaki, Y. *See* Sugiyama, A.

Park, M.K. *See* Rhee, J.C.

Rhee, J.C., Rhee, P.L., Park, M.K., So, I., Uhm, D.Y., Kim, K.W. and Kang, T.M.
Muscarinic receptors controlling I_{CCh} 331
Rhee, P.L. *See* Rhee, J.C.

Saitoh, N. *See* Nishiwaki, H.
Sakaguchi, M. *See* Takai, S.
Sakurai-Yamashita, Y. *See* Takeda, M.
Sasaki, K. *See* Miyake, N.
Sasaki, Y. *See* Goshima, Y.

Satoh, M., Takayanagi, I. and Koike, K.
Ca^{2+} oscillations in ileal cells 317
Sawaki, K. *See* Yamagishi, H.
Sekine, T. *See* Cha, S.H.
Shang, X.Y. *See* Wang, Q.L.
Shimizu, M. *See* Furukawa, N.
Shinoda, H. *See* Takahashi, A.
Shoda, R. *See* Uchida, M.
So, I. *See* Rhee, J.C.
Sugaya, K., Uz, T., Kumar, V. and Manev, H.
Anti-inflammatory therapies in AD 85
Sugimoto, Y. *See* Ishizawa, K.
Sugiyama, A., Aye, N.N., Yatomi, Y., Ozaki, Y. and Hashimoto, K.
Cardiovascular effects of Sph-1-P 338
Sugiyama, A., Lurie, K.G., Efange, S.M.N., Takahara, A., Takehana, S. and Hashimoto, K.
Dromotropic effects of MIBT 150
Sugiyama, Y. *See* Furukawa, N.
Sumi, S. *See* Takai, S.
Suwa, K. *See* Arakida, Y.
Suzuki, F. *See* Furukawa, N.
Suzuki, T. *See* Takeda, M.

Taira, E. *See* Niu, S-.Y.
Takahara, A. *See* Sugiyama, A.
Takahashi, A., Onodera, K., Shinoda, H. and Mayanagi, H.
Phenytoin and bone resorption 82
Takai, S., Sumi, S., Aoki, M., Sakaguchi, M., Itoh, Yoshimi, Jin, D., Matsumura, E. and Miyazaki, M.
Recombinant human chymase 144
Takaoka, M. *See* Kuro, T.
Takayanagi, I. *See* Satoh, M.
Takayanagi, M. *See* Miyake, N.
Takayanagi, Y. *See* Miyake, N.
Takeda, M., Tsukamoto, K., Sakurai-Yamashita, Y., Suzuki, T. and Taniyama, K.
SK-951 as 5-HT_4 agonist 138
Takeda, R. *See* Haji, A.
Takehana, S. *See* Sugiyama, A.
Takeuchi, T. *See* Nakagawa, M.
—— *See* Nishiwaki, H.
Tamura, T. *See* Yoshimura, M.
Tanaka, H. *See* Tsukimi, Y.
Tang, S.W. *See* Helmeste, D.M.
Taniguchi, M. *See* Guo, L.-Q.
Taniyama, K. *See* Takeda, M.
Tokuno, T., Muraki, K., Watanabe, Minoru and Imaizumi, Y.
Ischemia and benidipine in cardiac myocytes 199
Tsai, J.-J. *See* Wu, H.-M.
Tsuboi, M. *See* Kurogouchi, F.
Tsukamoto, K. *See* Takeda, M.
Tsukimi, Y., Ushiro, T., Yamazaki, T., Ishikawa, H., Hirasa, J., Narita, M., Nishigaito, T., Banno, K., Ichihara, T. and Tanaka, H.
Gastric H^+,K^+-ATPase and SPI-447 21

Uchida, M., Kato, Yumi, Matsueda, K., Shoda, R., Muraoka, A. and Yamato, S.
Diarrhea by castor oil and n-NOS 168
Ueno, T. and Yoshimura, T.
Physiological activities of DNIC 95
Uhm, D.Y. *See* Rhee, J.C.
Ushiro, T. *See* Tsukimi, Y.
Uz, T. *See* Sugaya, K.

Wang, Q.L., Shang, X.Y., Zhang S.L., Ji, J.B., Cheng, Y.N., Meng, Y.J. and Zhu, Y.J.
LMWH and airway allergic inflammation 326
Watanabe, Masahito *See* Yamagishi, H
Watanabe, Minoru *See* Tokuno, T.
Watanabe, T. *See* Katoh, Yoko
Watanabe, Y. *See* Kinoshita, K.
Wessale, J.L. *See* Kuro, T.
Wu, H.-M., Huang, C.-C., Li, L.-H., Tsai, J.-J. and Hsu, K.-S.
TW-001 exerts anticonvulsant effect 247

Xiao, Y.-Q. *See* Guo, L.-Q.

Yamada, S. *See* Morohashi, T.
Yamada, T. *See* Arakida, Y.
Yamagishi, H., Watanabe, Masahito, Yazaki, K., Sawaki, K. and Kawaguchi, M.
[^{3}H]PK14105 binding site in salivary gland 110
Yamaguchi, Y., Kagota, S., Haginaka, J. and Kunitomo, M.
Peroxynirite-generating species in CSE 78
Yamaji, M. *See* Nakagawa, M.
Yamanaka, S. *See* Miura, K.
Yamano, S. and Baum, B.J.
Gene-based salivary gland therapeutics 281
Yamato, S. *See* Uchida, M.
Yamazaki, M. *See* Koriyama, Y.
Yamazaki, T. *See* Tsukimi, Y.
Yamazoe, Y. *See* Guo, L.-Q.
—— *See* Nakamura, T.
Yang, X.P. and Chiba, S.
NPY neuromodulation in splenic artery 67
Vasoconstriction by purinergic nerve 71
Yatomi, Y. *See* Sugiyama, A.
Yazaki, K. *See* Yamagishi, H.
Yokota, M. *See* Arakida, Y.
Yokotani, K. *See* Nishihara, M.
Yonehara, N. *See* Yoshimura, M.
Yoshimura, M., Yonehara, N., Ito, Takashi, Kawai, Y. and Tamura, T.
Capsaicin on inflammation and nociception 116
Yoshimura, T. *See* Ueno, T.

Zhang S.L. *See* Wang, Q.L.
Zhao, D. *See* Kurogouchi, F.
Zhu, Y.J. *See* Wang, Q.L.

SUBJECT INDEX

Volume 82 • 2000

Acetylcholine release 138, 343
3-Acetylpyridine 295
Acute renal failure 307
Adeno-associated virus 281
Adenosine triphosphate 181
Adenylate cyclase 338
α_{2A}-Adrenoceptor 130
Adrenocortical cell 210
Airway allergic inflammation 326
Amitriptyline 130
Amygdaloid kindling 48
β-Amyloid protein 301
Analgesia 130
Analgesic 116
Angiotensin II 144
Anti-allergy 29
Anti-inflammatory drug 85
Anti-ulcer action 218
Anti-ulcer drug 21
Antipsychotic drug 1
Arterial thrombosis 188
Asthma 287, 326
Ataxia 295
Atrioventricular node 150
Autoimmune disease 281
Axon guidance 273

Benidipine 199
Benzodiazepine receptor 110
Blood pressure 338
Bone anabolic effect 240
Bone resorption 82
Bone structure 54
Bronchial asthma 326
Bronchoalveolar lavage fluid 326

Ca^{2+} channel 102, 247, 317
Ca^{2+} entry 210
Ca^{2+} entry blocker 269
Ca^{2+} oscillation 15, 317
Ca^{2+} store 317
Ca^{2+} wave 15
Calcitonin 240
Calcium (cytosolic free) 181
Calmodulin 350
Calvaria 82
cAMP 301
Capacitative Ca^{2+} entry 210
Capsaicin cream 116
Capsaicin-sensitive afferent nerve 168
Carbachol 331
Carboxy-PTIO (carboxy-2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide) 261
Cardiac myocyte 102
Caster oil 168
Chai-Hu-Long-Ku-Mu-Li-Tan (TW-001) 247
Chitin 218
Chitosan 218
Chronotropism 155
Chymase 144
Cigarette smoke 78
Clobenpropit 48
Competitive L-DOPA antagonist 40
Conduction 150
Contraction 338
Corneal endothelium 181
Coronary blood flow 150
Cyclooxygenase 85
Cytochrom P450 3A 122
Cytochrome P450 232
Cytokine 281
Cytoprotection 218
Cytosolic free calcium 181

D4 1
Dementia 85
Diabetes 102
Diazepam 48
Dinitrosyl dithiolato iron complex 95
Dinitrosyl iron complex 95
DOPA cyclohexyl ester 40
Dopamine receptor 1
Doxorubicin-resistant K562 cell 265

Electrical abnormality 199
Endothelin-1 307
Endotoxic shock 261
Enkephalin 175
Eosinophil 326
Epileptiform activity 247
ET_A receptor 307
ET_B receptor 307
Exocytosis 301

Feces 350
Femoral bone 54
Fructooligosaccharide 54
Furanocoumarin 122

G-protein-coupled receptor 171
GABA 48
Gastrectomy 54
Gastric cytoprotection 218
Gene therapeutics 281
Glutamatergic and dopaminergic binding 40
Growth cone 273

H^+,K^+-ATPase inhibitor 21
Heart 155, 199
Heart rate 338
Heparin 326
Herbal medicine 122
Hippocampal neuron 301
Hippocampus 226
Histamine 48
5-Hydroxytryptamine$_4$ receptor 138

IgE 29
Ileal smooth muscle 317
Imipramine 130
Induction 232
Inflammation 85, 116, 326
Inhibition 122
Inhibitor 144
Inositol 1,4,5-trisphosphate receptor 15
Inotropism 155
Interleukin-4 29
Intestinal mucosa 232
Intracellular recording 353
m-(Iodobenzyl)trozamicol 150
Iron complex 95
Ischemia 199

K^+ channel 343
KB-R7943 (2-[2-[4-(4-nitrobenzyloxy) phenyl]ethyl]isothiourea methanesulfonate) 155

L-dopa antagonist 40
Leukotriene D_4 287
5-Lipoxygenase 85
Liver microsome (human) 122
Local cerebral glucose utilization 295
Low molecular weight heparin (LMWH) 326

m-(iodobenzyl)trozamicol (MIBT) 150
Mao-bushi-saishin-to 29
Microtubule 269
Morphine 34
Morphine withdrawal 175
3-Morpholinosydnonimine (SIN-1) 78
Mu-receptor 343
Multidrug resistance 265
Muscarinic autoinhibition 343
Muscarinic receptor subtype 331
Myenteric plexus 343
Myocyte 102

Na^+ channel 247
Na^+/Ca^{2+} exchanger 155
Naloxone 34
Neurofilament 34
Neurogenic inflammation 116
Neuropeptide Y 67
Neuropilin 273
Neuroregeneration 273
Nitric oxide (NO) 95, 261
7-Nitroindazole 168
S-Nitrosothiol 95
NMDA receptor 353
NO carrier 95
NO donor 95
Nonadrenergic, noncholinergic (NANC) relaxation 164
Nonselective cationic current 331
Nonsteroidal anti-inflammatory drug 85

Noradrenaline release 59, 226
NSP-513 ((*R*)-4,5-dihydro-5-methyl-6-[4-(2-propyl-3-oxo-1-cyclohexenyl)amino] phenyl-3(*2H*)-pyridazinone) 188
Nucleus accumbens 40
Nucleus tractus solitarii 40

Omeprazole 21
Osteopenia 240
1*H*-[1,2,4]Oxadiazolo[4,3-*a*]quinoxalin-1-one (ODQ) 164

P2X purinoceptor 71
Paired-pulse facilitation 247
Patch-clamp 102
PC12 cell 59
Periaqueductal gray 175
Periarterial nerve stimulation 67
Peripheral type benzodiazepine receptor 110
Peritoneal mast cell (rat) 74
Perivascular electric stimulation 71
Peroxynitrite 78
Phenytoin 82
Phosphodiesterase 3 188
Phospholipase C 15
Photoaffinity labeling 110
[^{3}H]PK14105 (1-(2-fluoro-5-nitrophenyl)-3-isoquinolinecarboxylic acid) 110
Platelet aggregation 188
Preproenkephalin mRNA 175
Proliferation 181
Promoter 34
Propentofylline 301
Protease-activated receptor (PAR) 74, 171
Protein kinase C 210, 317
PTH(1 – 34) 240
Purinoceptor 71

Receptor antagonist 287
Receptor polymorphism 1
Recombinant 144
Renal failure 307
Renal function 307
Reperfusion 199
Respiratory neuron 353
Rifampicin 232

Sabstance P 116
Salivary gland 110, 281
[^{125}I]SB207710 binding ([^{125}I]SB207710: (1-*n*-butyl-4-piperidinyl)methyl-8-amino-7-iodo-1,4-benzodioxane-5-carboxylate) 138
SCH28080 21
Schizophrenia 1
Semaphorin 273
SIN-1 (3-morpholinosydnonimine) 78
SK&F 96365 (1-{β-[3-(4-methoxyphenyl) propoxyl]-4-methoxyphenethyl}-1*H*-imidazole hydrochloride) 269
SK-951 ((–)4-amino-*N*-[2-(1-azabicyclo [3.3.0]octan-5-yl)ethyl]-5-chloro-2,3-dihydro-2-methylbenzo[*b*]furan-7-carboxamide hemifumarate) 138
SK-M-SH cell 34
Smooth muscle 317, 331
Sodium channel 247
Soluble guanylyl cyclase 164
Sphingosine 1-phosphate 338
SPI-447 (3-amino-5-methyl-2(2-methyl-3-thienyl)-imidazo[1,2-*a*]thieno[3,2-*c*] pyridine) 21
Spleen cell 29
Splenic artery (dog) 71
Steroid-induced osteopenia 240
Stomach (guinea pig) 138
Sympathetic cotransmission 67
Synaptic vesicle 59
Synaptophysin 59

T-588 ((*R*)-(–)-1-(benzo[*b*]thiophen-5-yl)-2-[2-(*N,N*-diethylamino)ethoxy]ethanol hydrochloride) 59
Taltirelin hydrate 295
Tamolarizine 265
Testosterone 6β-hydroxylation 232
Thrombin 74, 171
Thrombosis 188
Thromboxane A_2 (TXA_2) 226, 287
Thyrotropin-releasing hormone 295
Transcription factor 175
Tricyclic antidepressant 130
Troglitazone 102
Trypsin 171
Tryptase 171
TW-001 (*Chai-Hu-Long-Ku-Mu-Li-Tan*) 247
TXA_2 mimetic 226

U-46619 (9,11-dideoxy-9α,11α-methanoepoxy prostaglandin $F_{2\alpha}$) 226

Vesamicol 150
Virus (adeno-associated) 281

YM158 (3-[(4-*tert*-butylthiazol-2-yl) methoxy]-5′-[3-(4-chlorobenzenesulfonyl) propyl]-2′-(1*H*-tetrazol-5-ylmethoxy) benzanilide monosodium salt monohydrate) 287

Zaldaride maleate 350